Keyphrases
Netherlands
58%
Overall Survival
58%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
47%
Peripheral T-cell Lymphoma
44%
Cancer Registry
36%
Brentuximab Vedotin
29%
Salvage Chemotherapy
29%
Treatment Strategy
29%
Treatment Outcome
29%
Population-based Cohort Study
29%
Enteropathy-associated T-cell Lymphoma
29%
Confidence Interval
22%
Hazard Ratio
22%
Chemotherapy
22%
Etoposide
22%
Peripheral T-cell lymphoma-NOS
17%
Anaplastic Large Cell Lymphoma
17%
Progression-free Survival
17%
Lymphoma Patients
14%
Anaplastic Lymphoma Kinase-positive
11%
Angioimmunoblastic T-cell Lymphoma
11%
Second Relapse
11%
Second-line Treatment
11%
Overall Response Rate
11%
CHOEP
11%
Predictors of Poor Prognosis
7%
Primary Therapy
7%
Prednisone
7%
Cyclophosphamide
7%
Advanced Stage
7%
Period Analysis
7%
Poor Prognosis
7%
Limited-stage
7%
Doxorubicin
7%
Advanced Stage Disease
7%
5-year Survival
7%
Third-line Treatment
5%
Second Complete Remission
5%
Relapsed or Refractory
5%
Population-based Study
5%
Survival after Recurrence
5%
Optimal Treatment
5%
ALK-negative
5%
Histological Subtypes
5%
Relapse Risk
5%
Risk Reduction
5%
Early Relapse
5%
Medicine and Dentistry
Peripheral T-Cell Lymphoma
100%
Overall Survival
96%
Cohort Analysis
88%
Autologous Stem Cell Transplantation
58%
Anaplastic Large Cell Lymphoma
47%
Etoposide
47%
Cancer Registry
43%
Angioimmunoblastic T-Cell Lymphoma
37%
Brentuximab Vedotin
29%
Enteropathy-Associated T-Cell Lymphoma
29%
Radiation Therapy
19%
Progression Free Survival
17%
Hazard Ratio
17%
CHOP
16%
Allogeneic Stem Cell Transplantation
11%
Anaplastic Lymphoma Kinase
11%
Doxorubicin
9%
Vincristine
9%
Prednisone
9%
Cyclophosphamide
9%
Diseases
5%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
58%
Cohort Study
58%
Etoposide
47%
Peripheral T Cell Lymphoma
41%
Enteropathy Associated T Cell Lymphoma
29%
Anaplastic Large Cell Lymphoma
23%
Angioimmunoblastic T Cell Lymphoma
17%
Chemotherapy
17%
Vincristine
11%
Cyclophosphamide
11%
Prednisone
11%
Cancer Registry
11%
Doxorubicin
11%
Remission
5%
Diseases
5%